Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Biocon Biologics, a subsidiary of Biocon, has secured EU marketing authorisation for its Denosumab biosimilars Vevzuo and ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Because Wegovy’s approved uses have expanded, people want to know whether it’s safe for long-term use. Based on clinical trials, the risk of serious problems from taking Wegovy is low.

Group revenues came in at DKK 65.3 billion ($9.3 billion) – ahead of analyst expectations – with GLP-1 agonist Wegovy (semaglutide) contributing DKK 9.4 billion of the total.

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...